Norwood, Mass.-based Corbus Pharmaceuticals Inc.'s deal earlier this month with Kaken Pharmaceutical Co. Ltd., of Tokyo, to develop and commercialize lenabasum for systemic sclerosis (SS) and dermatomyositis (DM) in Japan shone more light on drug developers' prospects in the former indication, but interest already ran high in some quarters.